NEW YORK, April 23, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Costco Wholesale Corporation (NASDAQ: COST), Liberty Media Corp. (NASDAQ: LMCA), Apollo Education Group Inc. (NASDAQ: APOL), Yum! Brands Inc. (NYSE: YUM), and Myriad Genetics Inc. (NASDAQ: MYGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Costco Wholesale Corporation Analyst Notes
Costco Wholesale Corporation (Costco) announced that the Company will release its monthly sales results for the month of March 2014 on April 10, 2014. For the four-week reporting month of February ended March 2, 2014, the Company reported net sales of $7.90 billion versus $7.58 billion in the year ago period. Costco, along with its subsidiaries, is engaged in the operation of membership warehouses in the U.S. and Puerto Rico, Canada, the U.K., Mexico, Japan, Australia, and through majority owned subsidiaries in Taiwan and Korea. The full analyst notes on Costco Wholesale Corporation are available to download free of charge at:
Liberty Media Corp. Analyst Notes
On April 3, 2014, Liberty Media Corp. (Liberty Media), along with Barnes & Noble Inc. (Barnes & Noble), announced that Liberty Media has entered into agreements to reduce its stake in Barnes & Noble - largest book retailer in the U.S. The Company informed Barnes & Noble that it has sold the majority of its stake to qualified institutional buyers in accordance with the Rule 144A under the Securities Act, but will retain nearly 10% of its initial investment. The sale of stake is expected to close on April 8, 2014. Concurrently, Liberty Media's right to elect two preferred stock Directors to the Board of Barnes & Noble's along with consent rights and pre-emptive rights will cease on April 8, 2014. As a result, Greg Maffei will no longer serve the board as of the closing on April 8, 2014, while Mark Carleton has been re-elected to the Barnes & Noble Board, effective April 8, 2014. The full analyst notes on Liberty Media Corp. are available to download free of charge at:
Apollo Education Group Inc. Analyst Notes
On April 1, 2014, Apollo Education Group Inc. (Apollo Education) released its Q2 FY 2014 results (period ended February 28, 2014). The Company reported net revenue of $679.1 million in Q2 FY 2014, down 18.6% YoY. During the quarter, the Company's net revenue from University of Phoenix declined 21.2% YoY to $594.1 million. The Company's net income attributable to Apollo Education came in at $14.6 million or $0.13 per diluted share in Q2 FY 2014, compared to a net income of $13.5 million or $0.12 per diluted share in Q2 FY 2013. Going forward, the Company expects net revenue in the range of $3.0 billion - $3.1 billion and operating income of $400 million - $450 million, excluding the impact of special items for full year FY 2014. The full analyst notes on Apollo Education Group Inc. are available to download free of charge at:
Yum! Brands Inc. Analyst Notes
On March 31, 2014, Yum! Brands Inc. (Yum!) announced the release of its online 2013 Corporate Social Responsibility (CSR) Report. According to the Company, the CSR report emphasizes on the efforts of the Company in relation to its four strategic areas of focus: Food, People, Community, and Environment. The report features success stories of Yum! in interactive, info-graphic-style and video formats. The stories and examples in the report are mainly related to the global view of the Company and its CSR efforts, including its philanthropic cause, World Hunger Relief, which has become the world's largest private sector hunger relief effort, in support of the United Nations World Food Programme and other hunger relief agencies. Further, the Company has also declared the month of April as the CSR month. The full analyst notes on Yum! Brands Inc. are available to download free of charge at:
Myriad Genetics Inc. Analyst Notes
On April 2, 2014, shares in Myriad Genetics Inc. (Myriad) rallied 11.47% to end the trading session at $39.18 on high volumes. Myriad's share price got a boost from the Company's announcement that the Centers for Medicare and Medicaid Services (CMS) will pay $2,767 for the Company's gene-based tests for breast cancer, 37% more than the $2,021 CMS was paying for the tests. A total of 7.50 million shares were traded, which was significantly above its 30-day average volume of 2.14 million. Over the past one month, the stock has gained 7.98% outperforming the NASDAQ Composite which lost 0.64% over the same period. The full analyst notes on Myriad Genetics Inc. are available to download free of charge at:
About Analysts Review We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review